Peng Si-Qi, Wu Qian-Qian, Wang Wan-Yi, Zhang Yi-Lin, Zhou Rui-Ning, Liao Jun, Wei Jin-Xuan, Yang Yan, Shi Wen, Yang Jun-Lan, Wang Xiao-Xu, Wei Zhi-Yuan, Sun Jia-Xuan, Huang Lu, Fan Hong, Cai Hui, Wang Cheng-Kun, Li Xin-Hua, Li Ting-Song, Liu Bi-Cheng, Zhang Xiao-Liang, Wang Bin
Department of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, China.
Department of Physiology, School of Basic Medical Science, Nanjing Medical University, Nanjing, China.
J Clin Invest. 2025 Apr 29;135(13). doi: 10.1172/JCI188807. eCollection 2025 Jul 1.
The ATP6V0A4 gene encodes the a4 subunit of vacuolar H+-ATPase (V-ATPase), which mediates hydrogen ion transport across the membrane. Previous studies have suggested that mutations in ATP6V0A4 consistently result in a loss of function, impairing the hydrogen ion transport efficacy of V-ATPase and leading to distal renal tubular acidosis and sensorineural hearing loss. Here, we identified a 32-year-old male patient and his father, both of whom harbored a heterozygous ATP6V0A4 p.V512L mutation and exhibited hypochloremic metabolic alkalosis, acidic urine, and hypokalemia. Through a series of protein structural analyses and functional experiments, the V512L mutation was confirmed as a gain-of-function mutation in the ATP6V0A4 gene. V512-a4 increased a4 subunit expression abundance by enhancing V512L-a4 stability and reducing its degradation, which in turn potentiated the capacity of V-ATPase to acidify the tubular lumen, leading to acidic urine and metabolic alkalosis. Through mutant V512L-a4 subunit structure-based virtual and experimental screening, we identified F351 (C25H26FN3O2S), a small-molecule inhibitor specifically targeting the V512L-a4 mutant. In conclusion, we identified a gain-of-function mutation in the ATP6V0A4 gene, broadening its phenotypic and mutational spectrum, and we provide valuable insights into potential therapeutic approaches for diseases associated with ATP6V0A4 mutations.
ATP6V0A4基因编码液泡H⁺-ATP酶(V-ATP酶)的a4亚基,该亚基介导氢离子跨膜运输。先前的研究表明,ATP6V0A4基因的突变始终导致功能丧失,损害V-ATP酶的氢离子运输效率,进而导致远端肾小管酸中毒和感音神经性听力损失。在此,我们鉴定了一名32岁男性患者及其父亲,他们均携带杂合的ATP6V0A4 p.V512L突变,并表现出低氯性代谢性碱中毒、酸性尿和低钾血症。通过一系列蛋白质结构分析和功能实验,证实V512L突变是ATP6V0A4基因的功能获得性突变。V512-a4通过增强V512L-a4的稳定性并减少其降解来增加a4亚基的表达丰度,这反过来又增强了V-ATP酶酸化肾小管管腔的能力,导致酸性尿和代谢性碱中毒。通过基于突变型V512L-a4亚基结构的虚拟筛选和实验筛选,我们鉴定出F351(C25H26FN3O2S),一种特异性靶向V512L-a4突变体的小分子抑制剂。总之,我们鉴定出ATP6V0A4基因的功能获得性突变,拓宽了其表型和突变谱,并为与ATP6V0A4突变相关疾病的潜在治疗方法提供了有价值的见解。